Climb Bio (CLYM) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Climb Bio (CLYM) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 503.3% versus a loss of 14.8%. Over five years, MNPR leads with a +242.1% price change compared with -32.7% for CLYM. Climb Bio is the larger company by market cap ($623.8 million vs $563.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | MNPR |
|---|---|---|
| Share price | $10.86 | $83.98 |
| Market cap | $623.76M | $563.69M |
| 1-day change | +1.40% | +0.24% |
| YTD return | +171.50% | +28.61% |
| 1-year return | +503.33% | -14.80% |
| 5-year return | -32.71% | +242.08% |
| EPS (TTM) | $-0.82 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $124.82 |
| 52-week low | $1.64 | $50.07 |
| Distance from 52-week high | -40.75% | -32.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +153.87% | +54.70% |
| Average volume | 1.37M | 215.52K |
| Shares outstanding | 57.44M | 6.71M |
| Employees | 28 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed MNPR by 518.1 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
CLYM vs MNPR FAQ
Which is bigger, Climb Bio or Monopar Therapeutics?
Climb Bio (CLYM) is larger, with a market capitalization of $623.76M compared with $563.69M for Monopar Therapeutics (MNPR).
Which stock has performed better over the past year, CLYM or MNPR?
CLYM returned +503.33% over the past 12 months, compared with -14.80% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.